Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Organ Dysfunctions
Authors:
- Daniil ZaytsevDZDaniil Zaytsev
- Larisa GirshovaLGLarisa Girshova
- Vladimir IvanovVIVladimir Ivanov
- Irina BudaevaIBIrina Budaeva
- Dmitri MotorinDMDmitri Motorin
- Renat BadaevRBRenat Badaev
- Julia MirolubovaJMJulia Mirolubova
- Tamara ChitanavaTCTamara Chitanava
- Ekaterina ZaykovaEZEkaterina Zaykova
- Julia AlexeevaJAJulia Alexeeva
- Andrey ZaritskeyAZAndrey Zaritskey
Preprint
- 2 October 2019
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Objectives: To demonstrate the efficacy of Gemtuzumab ozogamicin in refractory AML patients with organ dysfunctions and poor performance status. Three refractory AML patients with are described. One of them was pretreated by intensive chemotherapy, two other patients progressed during Azacitidine treatment. WHO performance status III . Two patients had respiratory failure grade 2, the other one suffered from acute kidney insufficiency. Two patients were highly febrile with elevated CRP level. Gemtuzumab ozogamicin administration was performed in three patients followed by further switch to Gemtuzumab ozogamicin + Azacitidine or “7+3” treatment. Results: Gemtuzumab ozogamicin administration resulted in abrupt fever cessation in two febrile patients simultaneously with CRP level decrease and fast gradual resolution of respiratory failure. Recovery of kidney function was noticed in patient with renal insufficiency. WHO performance status have elevated in all three patients. No adverse effects grade II-III were noticed. Further treatment made two patients eligible for intensive chemotherapy, one patient was transplanted, patient with kidney failure obtained complete remission. Conclusions: Gemtuzumab ozogamicin therapy appeared to be safe and highly efficacious in relapsed/refractory AML patients with organ dysfunctions and poor performance status.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab OzogamicinJournal of Pediatric Hematology/Oncology, 2019
- The Intensive Care Medicine research agenda on critically ill oncology and hematology patientsIntensive Care Medicine, 2017
- Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care UnitJAMA Oncology, 2017
- Immunotherapy: A promising approach to reverse sepsis-induced immunosuppressionPharmacological Research, 2016
- Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute LeukemiaClinical Lymphoma Myeloma and Leukemia, 2015
- Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage TherapyClinical Lymphoma Myeloma and Leukemia, 2013
- Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplantNature Clinical Practice Oncology, 2007
- Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase SykLeukemia, 2006
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrenceCancer, 2005
- Leukaemic pulmonary infiltrates in adult acute myeloid leukaemia: a high‐resolution computerized tomography studyBritish Journal of Haematology, 2003